Ibrexafungerp (SCY-078, MK-3118)

Showing 10 posts of 17 posts found.

Title

Date

Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

12 September 2014
SCYNEXIS starts phase 1 study to evaluate intravenous formulation of SCY-078

13 November 2015
Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.

15 July 2015
Scynexis’ (SCYX) SCY-078 Receives FDA Fast Track and QIDP Designations

28 January 2016
Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

19 January 2016
SCYNEXIS, Inc. Receives Orphan Drug Designation For SCY-078 For The Treatment Of Invasive Candida Infections

13 May 2016
Scynexis (SCYX) Announces Results from Two Completed SCY-078 Phase 2s; Closes $15 Term Loan

14 October 2016
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.

27 March 2017
A prospective, phase 2, multicentre, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vsstandard-of-care following initial intravenous echinocandin therapy in the treatment of..

27 April 2017
Evaluation of the antifungal activity of SCY-078 in combination with other antifungals against Aspergillus strains

27 April 2017

Back to New Antifungals